Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

NCT06163534 · View on ClinicalTrials.gov ↗

Study Summary

The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.

Study Locations (20)

California

  • City of Hope — Duarte
  • USC/Norris Comprehensive Cancer Center — Los Angeles
  • University of California, Los Angeles — Los Angeles
  • Stanford — Palo Alto
  • Providence Medical Foundation — Santa Rosa

Georgia

  • Morehouse — Atlanta
  • Piedmont Healthcare — Atlanta
  • Winship Cancer Institute, Emory University — Atlanta

Illinois

  • Northwestern University Feinberg School of Medicine — Chicago
  • Cancer Care Specialists of Illinois — Decatur
  • Illinois Cancer Care — Peoria

Missouri

  • Oncology Hematology Associates — Springfield
  • Washington University in St. Louis — St Louis

Kansas

  • University of Kansas — Westwood

Maryland

  • University of Maryland — Baltimore

Massachusetts

  • Dana Farber Cancer Institute — Boston

Michigan

  • Karmanos Cancer Institute — Detroit

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2024-08-01
Est. Completion 2028-03-01

Sponsor

Tempus AI

12 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06163534

The ClinicalTrials.gov registry entry for NCT06163534 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tempus AI, which has 12 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Head and Neck Squamous Cell Carcinoma appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06163534 reports 20 study locations spanning 11 distinct geographic areas — top geographies include California, Georgia, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06163534 about?

NCT06163534 is a clinical study titled "A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)". The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.

What is the current status of trial NCT06163534?

This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2024-08-01. Estimated completion is 2028-03-01.

What conditions does trial NCT06163534 study?

This clinical trial studies the following conditions: Head and Neck Squamous Cell Carcinoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT06163534?

This trial is sponsored by Tempus AI, which has 12 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06163534 being conducted?

This trial has 20 study locations across California, Georgia, Illinois, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial